The proteome of the cave bear
As a rule, it takes a genome to interpret a proteome.
A genome database gives the range of possible proteins that a sample is expected to contain, allowing a computer program to match short peptide fragments from the raw data to the full-length proteins they came from. The genome is like a picture showing how a jigsaw puzzle will look when it’s finished — and each peptide is a single tiny piece of the puzzle.
Richard Johnson, a staff scientist at the University of Washington’s department of genome sciences, has spent nearly three decades working with no picture. Before genomes were assembled and available, he became an expert in de novo peptide sequencing, piecing together the overlapping puzzle pieces from mass spectra to determine the amino acid sequence of proteins.
That ability has been coming in handy recently since Johnson started seeing more requests for environmental proteomics and other exotic analyses.
“I sit next to an oceanographer, and she does these proteomics analyses on strange samples, like glacial meltwater and seawater,” he said. “Those are cases where it’s really difficult to decide what database to even search.”
To annotate a sample from a human, a researcher can use a human genome database. But a tablespoon of ocean water or glacial runoff is likely to contain a complex community of microbes. So which genome databases should the researcher survey? Usually, researchers solve this problem by sequencing as much DNA as they can from a sample and using the result, a metagenome, to guide protein identification.
But even with a metagenome, sometimes the proteins observed in a proteomics experiment just don’t match the given reference database. “I came up with a metric that can tell you whether the protein sequence database is any good for interpreting your mass spectrometry data,” Johnson said.
The technique, which Johnson and colleagues recently published in Molecular & Cellular Proteomics, can be used to solve related problems, such as proteomic analysis of an animal whose genome has not been sequenced. “You typically use a sequence database from a closely related species and hope that the sequences did not diverge too much,” Johnson said. “Sometimes that hope is warranted, and other times it’s not.”
Johnson has used this approach to study the makeup of electrosensory organs in electric fish.
A third potential application is for analysis of very old but not fossilized tissues — those that come from extinct species, such as a vial of powdered cave bear bone that Johnson’s team obtained. Extinct species very rarely have a genome assembled, and the close-cousin conundrum is compounded by slow biochemical changes to proteins that happen over thousands of years.
But the approach doesn’t solve every problem. Johnson said, “Using this quality metric tells you how good or bad a sequence database is. But it won’t tell you what to do about it if it’s bad.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

The data that did not fit
Brent Stockwell’s perseverance and work on the small molecule erastin led to the identification of ferroptosis, a regulated form of cell death with implications for cancer, neurodegeneration and infection.

Building a career in nutrition across continents
Driven by past women in science, Kazi Sarjana Safain left Bangladesh and pursued a scientific career in the U.S.

Avoiding common figure errors in manuscript submissions
The three figure issues most often flagged during JBC’s data integrity review are background signal errors, image reuse and undeclared splicing errors. Learn how to avoid these and prevent mistakes that could impede publication.

Ragweed compound thwarts aggressive bladder and breast cancers
Scientists from the University of Michigan reveal the mechanism of action of ambrosin, a compound from ragweed, selectively attacks advanced bladder and breast cancer cells in cell-based models, highlighting its potential to treat advanced tumors.

Lipid-lowering therapies could help treat IBD
Genetic evidence shows that drugs that reduce cholesterol or triglyceride levels can either raise or lower inflammatory bowel disease risk by altering gut microbes and immune signaling.

Key regulator of cholesterol protects against Alzheimer’s disease
A new study identifies oxysterol-binding protein-related protein 6 as a central controller of brain cholesterol balance, with protective effects against Alzheimer’s-related neurodegeneration.